Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients (2024)

Renert-Yuval, Y., Ezzedine, K., Grimes, P., Rosmarin, D., Eichenfield, L. F., Castelo-Soccio, L., Huang, V., Desai, S. R., Walsh, S., Silverberg, J. I., Paller, A. S., Rodrigues, M., Weingarten, M., Narla, S., Gardner, J., Siegel, M., Ibad, S., & Silverberg, N. B. (2024). Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients. JAMA Dermatology, 160(4), 453-461. https://doi.org/10.1001/jamadermatol.2024.0021

Renert-Yuval, Yael ; Ezzedine, Khaled ; Grimes, Pearl et al. / Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients. In: JAMA Dermatology. 2024 ; Vol. 160, No. 4. pp. 453-461.

@article{7cd4d872fbbb4abbbb6f8ddd2de2a4d6,

title = "Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients",

abstract = "Importance: Evidence-based recommendations for the treatment of vitiligo in pediatric, adolescent, and young adult patients in the US are needed. Objective: To develop evidence- and consensus-based expert recommendations on the diagnosis and treatment of vitiligo in young patients. Evidence Review: A process was developed to produce consensus recommendations addressing questions regarding pediatric vitiligo. A librarian-conducted literature review was performed using articles that met the inclusion criteria: published in English, containing primary data (including meta-analysis) and pediatric-specific data, and analysis of 6 or more patients. Included articles were graded by the Strength of Recommendation Taxonomy criteria and Oxford Centre for Evidence-based Medicine's Levels of Evidence and Grades of Recommendation. Research questions were reviewed on May 9, 2022, through a video conference. One month after the conference, participants participated in an online survey documenting their level of agreement with the generated statements, using a 5-point Likert scale. Findings: Articles on topical corticosteroids and/or topical calcineurin inhibitors (n = 50), topical Janus kinase inhibitors (n = 5), pseudocatalase (n = 2), and microdermabrasion (n = 2) met inclusion criteria. Forty-two recommendations were made on the diagnosis of vitiligo and optimal topical therapeutics, with 33 recommendations obtaining a 70% or greater composite agreement and strong agreement. Topical calcineurin inhibitors twice daily, topical corticosteroids with time limitation due to atrophy risk, and topical ruxolitinib, 1.5%, cream - used off-label for patients younger than 12 years and limited to nonsegmental vitiligo - were identified as evidence-based first-line therapies in the management of pediatric and adolescent patients, with specific guidance on age-based data, minimum therapeutic trial of 6 months or greater, prolonged therapy to prevent recurrence, and the positive benefit of coordinated use of UV therapeutic sources. Conclusions and Relevance: Evidence supports the use of topical calcineurin inhibitors, topical corticosteroids, and topical Janus kinase inhibitors as effective therapeutics for vitiligo in pediatric, adolescent, and young adult patients, with specific decisions on choice of agent based on factors such as site location, body surface area, and age.",

author = "Yael Renert-Yuval and Khaled Ezzedine and Pearl Grimes and David Rosmarin and Eichenfield, {Lawrence F.} and Leslie Castelo-Soccio and Victor Huang and Desai, {Seemal R.} and Samantha Walsh and Silverberg, {Jonathan I.} and Paller, {Amy S.} and Michele Rodrigues and Mark Weingarten and Shanthi Narla and Jackie Gardner and Michael Siegel and Sidra Ibad and Silverberg, {Nanette B.}",

note = "Publisher Copyright: {\textcopyright} 2024 American Medical Association. All rights reserved.",

year = "2024",

month = apr,

day = "17",

doi = "10.1001/jamadermatol.2024.0021",

language = "אנגלית",

volume = "160",

pages = "453--461",

journal = "JAMA Dermatology",

issn = "2168-6068",

publisher = "American Medical Association",

number = "4",

}

Renert-Yuval, Y, Ezzedine, K, Grimes, P, Rosmarin, D, Eichenfield, LF, Castelo-Soccio, L, Huang, V, Desai, SR, Walsh, S, Silverberg, JI, Paller, AS, Rodrigues, M, Weingarten, M, Narla, S, Gardner, J, Siegel, M, Ibad, S & Silverberg, NB 2024, 'Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients', JAMA Dermatology, vol. 160, no. 4, pp. 453-461. https://doi.org/10.1001/jamadermatol.2024.0021

Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients. / Renert-Yuval, Yael; Ezzedine, Khaled; Grimes, Pearl et al.
In: JAMA Dermatology, Vol. 160, No. 4, 17.04.2024, p. 453-461.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients

AU - Renert-Yuval, Yael

AU - Ezzedine, Khaled

AU - Grimes, Pearl

AU - Rosmarin, David

AU - Eichenfield, Lawrence F.

AU - Castelo-Soccio, Leslie

AU - Huang, Victor

AU - Desai, Seemal R.

AU - Walsh, Samantha

AU - Silverberg, Jonathan I.

AU - Paller, Amy S.

AU - Rodrigues, Michele

AU - Weingarten, Mark

AU - Narla, Shanthi

AU - Gardner, Jackie

AU - Siegel, Michael

AU - Ibad, Sidra

AU - Silverberg, Nanette B.

N1 - Publisher Copyright:© 2024 American Medical Association. All rights reserved.

PY - 2024/4/17

Y1 - 2024/4/17

N2 - Importance: Evidence-based recommendations for the treatment of vitiligo in pediatric, adolescent, and young adult patients in the US are needed. Objective: To develop evidence- and consensus-based expert recommendations on the diagnosis and treatment of vitiligo in young patients. Evidence Review: A process was developed to produce consensus recommendations addressing questions regarding pediatric vitiligo. A librarian-conducted literature review was performed using articles that met the inclusion criteria: published in English, containing primary data (including meta-analysis) and pediatric-specific data, and analysis of 6 or more patients. Included articles were graded by the Strength of Recommendation Taxonomy criteria and Oxford Centre for Evidence-based Medicine's Levels of Evidence and Grades of Recommendation. Research questions were reviewed on May 9, 2022, through a video conference. One month after the conference, participants participated in an online survey documenting their level of agreement with the generated statements, using a 5-point Likert scale. Findings: Articles on topical corticosteroids and/or topical calcineurin inhibitors (n = 50), topical Janus kinase inhibitors (n = 5), pseudocatalase (n = 2), and microdermabrasion (n = 2) met inclusion criteria. Forty-two recommendations were made on the diagnosis of vitiligo and optimal topical therapeutics, with 33 recommendations obtaining a 70% or greater composite agreement and strong agreement. Topical calcineurin inhibitors twice daily, topical corticosteroids with time limitation due to atrophy risk, and topical ruxolitinib, 1.5%, cream - used off-label for patients younger than 12 years and limited to nonsegmental vitiligo - were identified as evidence-based first-line therapies in the management of pediatric and adolescent patients, with specific guidance on age-based data, minimum therapeutic trial of 6 months or greater, prolonged therapy to prevent recurrence, and the positive benefit of coordinated use of UV therapeutic sources. Conclusions and Relevance: Evidence supports the use of topical calcineurin inhibitors, topical corticosteroids, and topical Janus kinase inhibitors as effective therapeutics for vitiligo in pediatric, adolescent, and young adult patients, with specific decisions on choice of agent based on factors such as site location, body surface area, and age.

AB - Importance: Evidence-based recommendations for the treatment of vitiligo in pediatric, adolescent, and young adult patients in the US are needed. Objective: To develop evidence- and consensus-based expert recommendations on the diagnosis and treatment of vitiligo in young patients. Evidence Review: A process was developed to produce consensus recommendations addressing questions regarding pediatric vitiligo. A librarian-conducted literature review was performed using articles that met the inclusion criteria: published in English, containing primary data (including meta-analysis) and pediatric-specific data, and analysis of 6 or more patients. Included articles were graded by the Strength of Recommendation Taxonomy criteria and Oxford Centre for Evidence-based Medicine's Levels of Evidence and Grades of Recommendation. Research questions were reviewed on May 9, 2022, through a video conference. One month after the conference, participants participated in an online survey documenting their level of agreement with the generated statements, using a 5-point Likert scale. Findings: Articles on topical corticosteroids and/or topical calcineurin inhibitors (n = 50), topical Janus kinase inhibitors (n = 5), pseudocatalase (n = 2), and microdermabrasion (n = 2) met inclusion criteria. Forty-two recommendations were made on the diagnosis of vitiligo and optimal topical therapeutics, with 33 recommendations obtaining a 70% or greater composite agreement and strong agreement. Topical calcineurin inhibitors twice daily, topical corticosteroids with time limitation due to atrophy risk, and topical ruxolitinib, 1.5%, cream - used off-label for patients younger than 12 years and limited to nonsegmental vitiligo - were identified as evidence-based first-line therapies in the management of pediatric and adolescent patients, with specific guidance on age-based data, minimum therapeutic trial of 6 months or greater, prolonged therapy to prevent recurrence, and the positive benefit of coordinated use of UV therapeutic sources. Conclusions and Relevance: Evidence supports the use of topical calcineurin inhibitors, topical corticosteroids, and topical Janus kinase inhibitors as effective therapeutics for vitiligo in pediatric, adolescent, and young adult patients, with specific decisions on choice of agent based on factors such as site location, body surface area, and age.

UR - http://www.scopus.com/inward/record.url?scp=85188005056&partnerID=8YFLogxK

U2 - 10.1001/jamadermatol.2024.0021

DO - 10.1001/jamadermatol.2024.0021

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 38477910

AN - SCOPUS:85188005056

SN - 2168-6068

VL - 160

SP - 453

EP - 461

JO - JAMA Dermatology

JF - JAMA Dermatology

IS - 4

ER -

Renert-Yuval Y, Ezzedine K, Grimes P, Rosmarin D, Eichenfield LF, Castelo-Soccio L et al. Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients. JAMA Dermatology. 2024 Apr 17;160(4):453-461. doi: 10.1001/jamadermatol.2024.0021